SK Biopharmaceuticals Co., Ltd. (326030.KS) on Thursday reported a significant jump in first-quarter earnings, mainly driven by strong revenue growth.
Net income from continuing operation before income tax surged 391.6% to 99.978 billion won from 20.337 billion won in the prior-year quarter.
Operating profit jumped 249.7% to 89.768 billion won from 25.672 billion won a year earlier.
Net income attributable to shareholders of the parent company climbed 351.2% to 105.162 billion won from 23.305 billion won in the corresponding quarter last year.
Revenue rose 57.8% to 227.886 billion won from 144.377 billion won a year earlier.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.